Search research articles
Contact Us
Filters
Showing results (381-390 of 474) with videos related to
Page
of 48
Sort By:
Tuberculosis (Edinburgh, Scotland)
|
August 18, 2009
High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting
Jayne S Sutherland, David J Jeffries, Simon Donkor, et al.
The European Respiratory Journal
|
October 24, 2015
No added value of interferon-γ release to a prediction model for childhood tuberculosis
Toyin O Togun, Uzochukwu Egere, Marie P Gomez, et al.
Frontiers in Immunology
|
December 10, 2021
Major Neutrophil-Derived Soluble Mediators Associate With Baseline Lung Pathology and Post-Treatment Recovery in Tuberculosis Patients
Caleb Nwongbouwoh Muefong, Olumuyiwa Owolabi, Simon Donkor, et al.
Tetrahedron Letters
|
February 10, 2022
Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of <i>Mycobacterium tuberculosis</i>. Structural correction of reported <i>N</i>-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-<i>α</i>]pyrimidin-7-amine
Peter J Choi, Guo-Liang Lu, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry
|
November 13, 2010
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Iveta Kmentova, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry
|
March 18, 2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Brian D Palmer, Hamish S Sutherland, Adrian Blaser, et al.
Environmental Science & Technology
|
March 22, 2012
Earthworms and humans in vitro: characterizing evolutionarily conserved stress and immune responses to silver nanoparticles
Yuya Hayashi, Péter Engelmann, Rasmus Foldbjerg, et al.
FEMS Immunology and Medical Microbiology
|
December 19, 2000
Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease
A M Alkout, E J Ramsay, D A Mackenzie, et al.
Journal of Medicinal Chemistry
|
August 18, 2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)
Andrew M Thompson, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry
|
December 14, 2011
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Adrian Blaser, Brian D Palmer, Hamish S Sutherland, et al.
Page
of 48
Search research articles
Search
Showing results (381-390 of 474) with videos related to
Sort By:
Page
of 48
Tuberculosis (Edinburgh, Scotland)
|
August 18, 2009
High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting
Jayne S Sutherland, David J Jeffries, Simon Donkor, et al.
The European Respiratory Journal
|
October 24, 2015
No added value of interferon-γ release to a prediction model for childhood tuberculosis
Toyin O Togun, Uzochukwu Egere, Marie P Gomez, et al.
Frontiers in Immunology
|
December 10, 2021
Major Neutrophil-Derived Soluble Mediators Associate With Baseline Lung Pathology and Post-Treatment Recovery in Tuberculosis Patients
Caleb Nwongbouwoh Muefong, Olumuyiwa Owolabi, Simon Donkor, et al.
Tetrahedron Letters
|
February 10, 2022
Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of <i>Mycobacterium tuberculosis</i>. Structural correction of reported <i>N</i>-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-<i>α</i>]pyrimidin-7-amine
Peter J Choi, Guo-Liang Lu, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry
|
November 13, 2010
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Iveta Kmentova, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry
|
March 18, 2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Brian D Palmer, Hamish S Sutherland, Adrian Blaser, et al.
Environmental Science & Technology
|
March 22, 2012
Earthworms and humans in vitro: characterizing evolutionarily conserved stress and immune responses to silver nanoparticles
Yuya Hayashi, Péter Engelmann, Rasmus Foldbjerg, et al.
FEMS Immunology and Medical Microbiology
|
December 19, 2000
Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease
A M Alkout, E J Ramsay, D A Mackenzie, et al.
Journal of Medicinal Chemistry
|
August 18, 2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)
Andrew M Thompson, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry
|
December 14, 2011
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Adrian Blaser, Brian D Palmer, Hamish S Sutherland, et al.
Page
of 48